Drug Profile
MIN 301
Alternative Names: MIN-301; NRG-101Latest Information Update: 22 May 2023
Price :
$50
*
At a glance
- Originator ProteoSys
- Developer Minerva Neurosciences; ProteoSys
- Class Antidementias; Antiparkinsonians; Antipsychotics; Neuregulins; Neuroprotectants; Recombinant proteins
- Mechanism of Action ERBB 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
- Discontinued Alzheimer's disease; CNS disorders; Schizophrenia
Most Recent Events
- 16 May 2023 Preclinical trials in Parkinson's disease in Switzerland (IV) (Minerva Neurosciences pipeline, May 2023)
- 16 May 2023 Preclinical trials in Parkinson's disease in Switzerland (SC) (Minerva Neurosciences pipeline, May 2023)
- 08 Mar 2023 Minerva Neurosciences has patent protection for MIN 301 in Japan and Mexico